10-1074 vs 3BNC117

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV envelope · full HIV pipeline

10-1074

Developed by Gilead Sciences under a licence from The Rockefeller University

Phase 2 in HIVmonoclonal antibody
Weak signal

NCT03707977 · Phase 1/2 · completed

This was a small, nonrandomized, open-label study without a comparator arm, enrolling 30 children overall and evaluating viral-load and safety outcomes descriptively. All participants received 10-1074 together with a second antibody, VRC01LS, so the results describe the dual-antibody regimen, not 10-1074 alone. The primary viral outcomes were reported as 11 of 25 below 400 copies/mL and 10 of 25 below 40 copies/mL at Week 24, but there was no controlled comparison or formal significance test.

Reported efficacy

Frequency of Treatment-associated Adverse Events (AEs) [Number of Participants With Treatment-associated Adverse Event(s) of Any Grade] (Measured until 30 days after study completion for each participant); Severity of Treatment-associated AEs (Number of Participants With Grade 3 or Higher Related AEs) (Measured until 30 days after study completion for each participant); Proportion of Children Who Maintain HIV-1 Plasma RNA Less Than 400 Copies/mL, After Initiating VRC01LS and 10-1074 Infusions and Stopping ART (Measured through Week 24 of Step 2); Proportion of Children Who Maintain HIV-1 Plasma RNA Less Than 40 Copies/mL, After Initiating VRC01LS and 10-1074 Infusions and Stopping ART (Measured through Week 24 of Step 2): Frequency of Treatment-associated Adverse Events (AEs) [Number of Participants With Treatment-associated Adverse Event(s) of Any Grade] (Measured until 30 days after study completion for each participant): Group PK-A: ART + VRC01LS 4 Participants | Group PK-B: ART + 10-1074 1 Participants | Steps 1-3 Participants (ART + 10-1074 + VRC01LS) 19 Participants (not_applicable)

Result source: NCT03707977

3BNC117

Developed by Frontier Biotechnologies and partners

Phase 2 in HIVmonoclonal antibody
Partial signal

NCT03041012 · Phase 2 · completed

This open-label, randomized Phase 1b/2a trial assigned 55 people newly diagnosed with HIV-1 to four groups: standard antiretroviral therapy alone, or with the antibody 3BNC117, romidepsin, or both. The first primary measure, the early fall in blood virus levels, was faster with 3BNC117 plus romidepsin than with therapy alone between days 10 and 24 (P=0.048). The second primary measure, the number of immune cells that carry intact virus after one year, fell in all groups, with no significant difference between groups. Because one primary measure was met and one was missed, the result is mixed. The figures come from the peer-reviewed report of the trial in Nature Medicine.

Reported efficacy

Plasma HIV RNA kinetics (3 months); Quantification of the size of the proviral HIV reservoir (1 year); Time to viral rebound during ATI (12 weeks): Co-primary 1, plasma HIV-1 RNA decay rate, ART+romidepsin+3BNC117 vs ART only: daily decay 16.9% (95% CI -27.3% to -4.93%) vs 10.0% (95% CI -14.9% to -4.86%) from day 10 to 24 (P=0.048); comparable from day 0 to 10 and day 24 to 90, met. Co-primary 2, change in intact HIV-1 provirus frequency from baseline to day 365: all groups decreased, with no significant differences between the groups, missed. (mixed)

Result source: NCT03041012

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpoint10-10743BNC117
HIV-1 RNA below 50 copies/mL (week 48)—Not reported—Not reported
HIV-1 RNA 50 copies/mL or more (week 48)—Not reported—Not reported
CD4 count, change (week 48)—Not reported—Not reported

HIV-1 RNA below 50 copies/mL (week 48)

10-1074
—Not reported
3BNC117
—Not reported

HIV-1 RNA 50 copies/mL or more (week 48)

10-1074
—Not reported
3BNC117
—Not reported

CD4 count, change (week 48)

10-1074
—Not reported
3BNC117
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. 10-1074: 3 of 4 rows · 3BNC117: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metric10-10743BNC117
Dropout rate
0%Group PK-B: ART + 10-1074
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
show 3 more results
—PK Step (ART + 10-1074)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
—Step 1 (ART + VRC01LS + 10-1074)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
—Step 2 (VRC01LS + 10-1074 Only)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
11.8%a
NCT02588586 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
0%Group A: 3BNC117 IV + ART Interrup
NCT02446847 · Phase 2 · registry result, not featured evidence · combination
25%Group B: 3BNC117 IV + ART Interrup
NCT02446847 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—Group PK-B: ART + 10-1074
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
show 3 more results
—PK Step (ART + 10-1074)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
—Step 1 (ART + VRC01LS + 10-1074)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
—Step 2 (VRC01LS + 10-1074 Only)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
—a
NCT02588586 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
—Group A: 3BNC117 IV + ART Interrup
NCT02446847 · Phase 2 · registry result, not featured evidence · combination
—Group B: 3BNC117 IV + ART Interrup
NCT02446847 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
—Group PK-B: ART + 10-1074
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
show 3 more results
0%PK Step (ART + 10-1074)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
0%Step 1 (ART + VRC01LS + 10-1074)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
4%Step 2 (VRC01LS + 10-1074 Only)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
5.9%a
NCT02588586 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
0%Group A: 3BNC117 IV + ART Interrup
NCT02446847 · Phase 2 · registry result, not featured evidence · combination
12.5%Group B: 3BNC117 IV + ART Interrup
NCT02446847 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
rhinorrhoea 83.3%
cough 50%
pyrexia 50%
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
show 2 more results
neutrophil count decreased 35.7%
haemoglobin decreased 28.6%
cough 25%
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
cough 44%
upper respiratory tract infection 32%
haemoglobin decreased 28%
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
a
malaise 23.5%
nausea 23.5%
diarrhea 17.6%
NCT02588586 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
headache 75%
upper respiratory tract infection 62.5%
paresthesia upper extremity 37.5%
NCT02446847 · Phase 2 · registry result, not featured evidence · combination
upper respiratory tract infection 75%
headache 25%
anemia 12.5%
NCT02446847 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

3BNC117

Viral Rebound 86.7% (n=15) @ 36wk
event count · % of participants
No placebo or comparator arm
NCT02588586 · Phase 2 · registry result, not featured evidence · combination · converted to % from 13 Participants as posted
Time to Viral Rebound 1.27 months @ 36wk
time to event · months
No placebo or comparator arm
NCT02588586 · Phase 2 · registry result, not featured evidence · combination · converted to months from 5.5 weeks as posted
Virologic Rebound 66.7% (n=6) @ 8wk
event count · % of participants
No placebo or comparator arm
NCT02446847 · Phase 2 · registry result, not featured evidence · combination · converted to % from 4 Participants as posted
show 1 more result
37.5% (n=8) @ 8wk*
NCT02446847 · Phase 2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 10-1074's landscape · 3BNC117's landscape